The US National Institute of Allergy and Infectious Diseases (NIAID) and pharmaceutical company Merck have begun enrolling around 1500 people at high risk of contracting HIV in a multicountry phase II trial of an investigational HIV/AIDS vaccine. The vaccine uses an adenovirus—a common cold virus—for the delivery of three synthetic HIV genes, gag, pol, and nef, into cells.